SAGE: Effect of a Two-month Carbohydrate-restricted Diet on Energy Metabolism in a Seniors' Residence

Sponsor
Université de Sherbrooke (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06022094
Collaborator
(none)
25
1
1
10.2
2.5

Study Details

Study Description

Brief Summary

The present study will assess the effects on glucose, ketones and other blood biomarkers fuels, cognition, quality of life, physical activity and well-being of a reduced carbohydrate menu (R-CHO) for 2 months in a population living in a residence for the elderly. This intervention study, identified as the SAGE project (phase 2), follows on from the Ketohome project (phase 1) assessing the feasibility of such a project.

Condition or Disease Intervention/Treatment Phase
  • Other: 2 months of reduced carb menus
N/A

Detailed Description

Finding an effective therapeutic strategy for Alzheimer's disease (AD) is a societal priority, but it also remains a major challenge. With one exception in 2021, no new pharmaceutical treatment for AD has been approved for over 20 years. However, several clinical trials demonstrate the potential of ketogenic interventions to restore brain energy and improve cognition in people with mild cognitive impairment and AD. Recently, the largest and longest clinical trial of its kind shows that compensating for energy deficit in the brain during aging improves brain metabolic and cognitive functioning in people with early AD and could potentially delay AD.

One of the main types of ketogenic intervention is the highly reduced carbohydrate (5-10% of daily energy value compared to a normal value of 50-65%) and very high fat ketogenic diet. Despite the now well-established safety of the ketogenic diet and its therapeutic value in the treatment of epilepsy and type 2 diabetes, the latter remains difficult to implement in because of the compliance challenge. A reduced glycemic load diet where intake of refined carbohydrates and added sugar is restricted is found to be much less restrictive than a ketogenic diet. Phase 1 of this project showed that decreased carbohydrate (sugar) intake may improve long-term glycemic control and compliance compared to more severe carbohydrate restriction. Having better blood glucose control may also be important in decreasing the risk of AD possibly by improving the metabolic profile and/or by promoting the production and use of ketones. However, its effectiveness in helping cognition in the elderly is still unknown and any changes in dietary habits can be addressed with some resistance.

The objective of this project is therefore to answer the following question: does a reduction in carbohydrates of 30 to 50% for 2 months reduce the risk of AD by improving the metabolic profile in people living in a senior residence?

Study Design

Study Type:
Interventional
Anticipated Enrollment :
25 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
All participants will eat a reduced carb menu for 2 monthsAll participants will eat a reduced carb menu for 2 months
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Effect of a Two-month Carbohydrate-restricted Diet on Energy Metabolism in a Seniors' Residence: The SAGE Study
Anticipated Study Start Date :
Sep 10, 2023
Anticipated Primary Completion Date :
Dec 15, 2023
Anticipated Study Completion Date :
Jul 15, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Delta of before/after the intervention

Data will be collected before and after the reduced carb intervention

Other: 2 months of reduced carb menus
Participants will eat a reduced carb menu for 2 months
Other Names:
  • R-CHO
  • Outcome Measures

    Primary Outcome Measures

    1. Change in blood glucose levels [2 months]

      Blood glucose will be monitored continuously with a real-time continuous glucose monitor (CGM) for two 10-days periods; before/after intervention in people in a senior residence.

    2. Change in blood ketones levels [2 months]

      Blood ketones will be measured before/after the intervention in people in a senior residence via blood sampling.

    3. Change in blood insulin levels [2 months]

      Blood insulin will be measured before/after the intervention in people in a senior residence via blood sampling.

    Secondary Outcome Measures

    1. Change in blood triglycerides levels, [2 months]

      Blood triglycerides levels will be measured before/after the intervention in people in a senior residence via blood sampling.

    2. Change in blood cholesterol levels [2 months]

      Blood cholesterol levels will be measured before/after the intervention in people in a senior residence via blood sampling.

    3. Change in blood glycated hemoglobin levels [2 months]

      Blood glycated hemoglobin levels will be measured before/after the intervention in people in a senior residence via blood sampling.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    60 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Senior men or women residing in VÜ resident home;

    • Understand, read and write French;

    • Possess sufficient visual and auditory acuity to pass the cognitive tests;

    • Available during the intervention period

    Exclusion Criteria:
    • Body mass index < 20;

    • T1 diabetic;

    • Insulin-dependent T2 diabetic;

    • Mini Mental State Exam (MMSE) < 20;

    • Weight loss >10% in the last 6 months, involuntary or voluntary;

    • Known and uncontrolled hypoglycaemia;

    • Moderate to severe digestive illnesses that may be aggravated by dietary changes;

    • Severe dysphagia;

    • Supplementation with medium chain triglycerides oil, ketone salts, ketone ester, adherence to the ketogenic diet, reduced carbohydrate diet, intermittent fasting, or other diet or supplements that may significantly increase ketones in the past month;

    • Participation in other intervention research projects on nutrition or aimed at metabolic change simultaneously.

    • Medical condition that could prevent the participant from completing the study according to the doctor's opinion

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Research Center on Aging Sherbrooke Quebec Canada J1H 4C4

    Sponsors and Collaborators

    • Université de Sherbrooke

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Université de Sherbrooke
    ClinicalTrials.gov Identifier:
    NCT06022094
    Other Study ID Numbers:
    • 2024-5195
    First Posted:
    Sep 1, 2023
    Last Update Posted:
    Sep 1, 2023
    Last Verified:
    Aug 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Université de Sherbrooke

    Study Results

    No Results Posted as of Sep 1, 2023